Allergies

The Learning Early About Peanut Allergy trial randomised 640 high-risk infants aged four to eleven months to either regular peanut consumption or peanut avoidance. At five years of age, peanut allergy had developed in 17.2% of the avoidance group but only 3.2% of the consumption group, an eighty one percent reduction. The protective effect was consistent regardless of the infant's skin sensitivity status at enrolment. The results directly contradicted existing UK and US clinical guidance at the time, which advised peanut avoidance in high-risk infants.

Follow-up analysis showed that consumption between twelve and sixty months produced the most durable protection. The LEAP findings prompted revision of allergy guidelines internationally. The US National Institute of Allergy and Infectious Diseases issued updated recommendations in 2017 endorsing early introduction for high-risk infants. UK guidelines were revised in parallel. The trial is the clearest evidence that delayed introduction strategies, followed for decades as precautionary policy, increased rather than decreased allergy prevalence across the same period.

The LEAP trial randomised six hundred and forty infants at high allergy risk to either consume or avoid peanuts from early infancy. Those given early exposure had an eighty-one per cent lower rate of peanut allergy by age five.

This is because early oral exposure activates gut-associated regulatory T-cells that establish tolerance before sensitisation can occur through the skin barrier.

The findings overturned two decades of clinical advice instructing parents to delay allergen introduction, prompting major guideline revisions across the UK, US and Australia.

The LEAP trial (Du Toit et al., 2015, New England Journal of Medicine) randomised 640 high-risk infants aged four to eleven months to either consume peanut-containing foods three or more times per week or completely avoid peanuts until age five. At age five, peanut allergy prevalence was 3.2 per cent in the consumption group versus 17.2 per cent in the avoidance group, a relative reduction of eighty-one per cent (p<0.001). The LEAP-On follow-up showed the protection persisted after twelve months of subsequent peanut avoidance.

This is because early oral exposure to food proteins induces immune tolerance through regulatory T cell generation in the gut-associated lymphoid tissue (GALT). The infant immune system is biased toward tolerance in the first year of life; environmental antigens encountered orally during this window are classified as harmless and generate Treg-mediated suppression of future IgE responses. Delayed introduction allows the first encounter to occur through skin (especially eczematous skin), which biases the immune response toward IgE sensitisation rather than tolerance.

Prior to this trial, the American Academy of Pediatrics (2000) recommended delaying peanut introduction until age three. This advice, based on expert opinion rather than evidence, may have directly caused the peanut allergy epidemic: UK peanut allergy prevalence tripled between 1989 and 2003 (Venter et al., 2010), precisely the period when avoidance guidelines were most widely followed. The AAP reversed its guidance in 2017. The epinephrine auto-injector market exceeded $2.7 billion in 2023 (Fortune Business Insights), treating a condition that early introduction prevents.

Turner et al. (2020) in the Journal of Allergy and Clinical Immunology analysed population-level data and estimated that peanut allergy prevalence in UK children increased from approximately 0.5 per cent in 1995 to 2.2 per cent in 2016, a roughly 350 per cent increase in 21 years. Similar trajectories have been documented in Australia (Osborne et al. 2011: 3.0 per cent prevalence in 12-month-olds) and the United States (Sicherer et al. 2010: from 0.4 per cent in 1997 to 1.4 per cent in 2010).

This is because allergy is fundamentally an immune misprogramming event: the immune system encounters a harmless protein (peanut arachin) and classifies it as a threat, producing IgE antibodies. Early-life immune programming depends on microbial diversity in the gut, skin exposure to food proteins and the timing of oral introduction. The LEAP trial (Du Toit et al. 2015) demonstrated that early peanut introduction (from 4 months) reduced peanut allergy by 81 per cent compared to avoidance: the previous recommendation to avoid peanuts until age 3 may have caused the very epidemic it intended to prevent.

Three environmental factors converge: antibiotic use in infancy (disrupting gut microbiome diversity), reduced microbial exposure (caesarean birth, formula feeding, sanitised environments) and delayed allergen introduction (medical advice that was reversed only in 2017). The allergy epidemic is not a mystery. It is a predictable consequence of systematically disrupting the immune programming sequence that human infants evolved to receive: vaginal birth microbiome, breast milk antibodies, early environmental exposure and diverse microbial colonisation.

A 2016 systematic review and meta-analysis of eighteen studies found that antibiotic use in the first year of life was associated with doubled eczema risk (OR 2.02) and a fifty one percent increase in childhood asthma risk. The relationship showed a dose-response pattern: three or more antibiotic courses before age one was associated with greater risk than one or two courses. The mechanism is disruption of early gut microbiome establishment during a critical immune-programming window.

Infants carry distinct gut microbiome communities through the first six months of life, populated predominantly by Bifidobacterium species that process human milk oligosaccharides and produce short-chain fatty acids that train regulatory T cells. Broad-spectrum antibiotics, particularly amoxicillin and co-amoxiclav, eliminate this consortium. Unlike adults, infants have limited resilience to this disruption because the ecological niche has not yet stabilised. UK prescribing data show that over thirty percent of infants receive at least one antibiotic course in their first twelve months.

A 2019 meta-analysis of eighty-three studies covering over 1.3 million births found that caesarean delivery was associated with a twenty percent higher risk of asthma, a twenty three percent higher risk of allergic rhinitis and a fifteen percent higher risk of atopic eczema compared to vaginal delivery. The mechanism is microbial: during vaginal birth the infant is colonised by Lactobacillus, Bifidobacterium and other maternal vaginal and intestinal bacteria that seed the infant gut microbiome. Caesarean-delivered infants are instead colonised primarily by skin and environmental bacteria.

The infant gut microbiome established in the first weeks of life directly trains the developing immune system to distinguish harmless environmental antigens from genuine threats. Disrupted early colonisation shifts immune development toward Th2-biased responses associated with allergic sensitisation. The effect is partially attenuated by breastfeeding, which delivers maternal immunoglobulins and additional microbiota. Some clinicians now perform "vaginal seeding," applying maternal vaginal swabs to caesarean-born infants, though controlled trial evidence for this intervention remains limited.

Tsakok et al. (2013, British Journal of Dermatology) conducted a meta-analysis of twenty studies involving over one million children and found that antibiotic exposure in the first year of life was associated with a fifty-two per cent increase in subsequent eczema risk (pooled OR 1.52, 95% CI 1.30 to 1.78). A dose-response relationship was observed: each additional antibiotic course further increased risk. The association was strongest for broad-spectrum antibiotics and earliest exposures (first three months of life).

This is because the infant gut microbiome undergoes a critical assembly phase in the first year of life, during which commensal bacterial colonisation trains the immune system to distinguish harmless antigens from pathogens. Antibiotics devastate this microbial assembly: Yassour et al. (2016, Science Translational Medicine) showed that a single antibiotic course reduced gut bacterial diversity by thirty per cent and eliminated specific Bifidobacterium and Bacteroides species essential for immune education. The depleted microbiome fails to generate adequate regulatory T cells, biasing the immune system toward Th2-driven allergic responses.

Antibiotic prescriptions for children under five total approximately 28.5 million per year in the US (CDC, 2023). An estimated thirty to fifty per cent of these are unnecessary (Fleming-Dutra et al., 2016, JAMA). Each unnecessary prescription carries a measurable probability of permanently altering the child's immune trajectory. The global eczema treatment market reached $13.6 billion in 2023 (Fortune Business Insights), treating a condition that early-life antibiotic overuse contributes to creating.

Marra et al. (2009) in Pediatrics meta-analysed 20 studies comprising over 38,000 children and found that exposure to at least one course of antibiotics in the first year of life was associated with a 52 per cent increased risk of childhood asthma (OR 1.52, 95% CI 1.30 to 1.78). The association showed a dose-response relationship: each additional antibiotic course increased asthma risk by a further 16 per cent. Broad-spectrum antibiotics carried higher risk than narrow-spectrum agents.

This is because the first year of life is the critical window for immune system education. The gut microbiome during this period is establishing the balance between Th1 (pathogen-fighting) and Th2 (allergy-promoting) immune responses. Antibiotics indiscriminately eliminate commensal bacteria, particularly Bifidobacterium and Bacteroides species, that suppress Th2 skewing. Arrieta et al. (2015) demonstrated in a mouse model that specific bacterial genera depleted by antibiotics (Lachnospira, Veillonella, Faecalibacterium, Rothia) were protective against atopic disease. Restoring these bacteria prevented asthma development.

In the UK, approximately 30 per cent of children receive at least one antibiotic prescription in their first year of life. Each prescription is prescribed for an acute infection (ear infection, chest infection, urinary tract infection) that is typically self-limiting. The acute benefit is modest. The downstream cost is a permanently altered immune trajectory: higher allergy risk, higher asthma risk, higher eczema risk. No prescribing guideline currently requires informed consent about long-term immune consequences of first-year antibiotic exposure.

A population cohort tracking over ten thousand UK children found peanut sensitisation tripled between 1989 and 2003, rising from 1% to over 3% in that period alone.

The increase coincides with the widespread adoption of avoidance advice as standard paediatric guidance, suggesting the advice itself may have accelerated sensitisation rates.

Environmental changes including reduced microbial exposure and increased skin barrier disruption also contributed, but the timing of the policy shift is a primary candidate for explanation.

Thavagnanam et al. (2008) in Clinical and Experimental Allergy meta-analysed 26 studies and found that caesarean delivery was associated with a 23 per cent increased risk of allergic rhinitis (OR 1.23, 95% CI 1.12 to 1.35) and a 21 per cent increased risk of asthma (OR 1.21, 95% CI 1.11 to 1.32). Bager et al. (2008) confirmed the asthma association in a separate meta-analysis of 23 studies. The UK caesarean rate has risen from 9 per cent in 1980 to 35 per cent in 2023 (NHS Maternity Statistics).

This is because vaginal birth exposes the neonate to the mother's vaginal and intestinal microbiome: primarily Lactobacillus, Bifidobacterium and Bacteroides species. These pioneer colonisers train the neonatal immune system to tolerate commensal organisms and distinguish harmless environmental proteins from genuine threats. Caesarean-born infants are instead colonised by skin and hospital environment bacteria: Staphylococcus, Clostridium and Streptococcus species. Jakobsson et al. (2014) showed that caesarean-born infants had significantly lower Bacteroidetes colonisation at one year and altered immune cell ratios.

The effect is dose-dependent across the population. When 9 per cent of births were caesarean, the population-level impact on allergy was small. At 35 per cent, more than one in three children begin life with a suboptimal microbiome and a measurably higher risk of allergic disease. The rising caesarean rate overlaps precisely with the allergy epidemic. The causal mechanism (absent microbial transfer → altered immune programming → increased atopic sensitisation) is documented at every step.

David Strachan's 1989 analysis of seventeen thousand British children found that hay fever and eczema were significantly less common in children from larger families, particularly those with older siblings.

This is because older siblings introduce diverse microbial challenges in early life, training the developing immune system towards infection-fighting Th1 responses rather than allergic Th2 responses.

The hygiene hypothesis framed by this study has since driven the entire field of allergy immunology, and remains the dominant explanatory model for the post-industrial allergy epidemic.

Neltner et al. (2013, JAMA Internal Medicine) analysed the regulatory basis for the approximately 10,000 substances permitted in the US food supply and found that for 3,000 of them, the safety determination was made entirely by the manufacturer or an industry-selected panel without FDA review, under the Generally Recognised as Safe (GRAS) designation. For an additional 1,000 substances, no publicly available safety data existed at all. The authors concluded that the GRAS process "does not ensure the safety of food additives."

This is because the 1958 Food Additives Amendment to the Federal Food, Drug, and Cosmetic Act created the GRAS exemption allowing manufacturers to self-certify substances as safe without FDA notification or review. The threshold for GRAS status requires "general recognition of safety" among qualified experts, but companies can satisfy this through private panels whose deliberations are not disclosed publicly. The FDA has no mandatory pre-market review process and no systematic post-market surveillance for the majority of food additives.

Allergic diseases (food allergy, eczema, asthma, allergic rhinitis) have increased dramatically since 1960 in industrialised nations. Food allergy prevalence in children increased by fifty per cent between 1997 and 2011 (CDC, 2013). The parallel introduction of thousands of untested synthetic compounds into the food supply, many of which are known to disrupt epithelial barrier function (emulsifiers, Chassaing et al. 2015), immune signalling (artificial colours, McCann et al. 2007) and gut microbiome composition (preservatives, Suez et al. 2014), represents a plausible contributing mechanism.